UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy

被引：0
|
作者：
Qianqian Yu
Tao Zhang
Conghua Xie
Hong Qiu
Bo Liu
Liu Huang
Ping Peng
Jueping Feng
Jigui Chen
Aihua Zang
Xianglin Yuan
机构：
[1] Huazhong University of Science and Technology,Department of Oncology, Tongji Hospital, Tongji Medical College
[2] Huazhong University of Science and Technology,Cancer Center, Union Hospital, Tongji Medical College
[3] Wuhan University,Department of Radiation and Medical Oncology, Zhongnan Hospital
[4] Huazhong University of Science and Technology,Department of Oncology, PuAi Hospital, Tongji Medical College
[5] Wuhan 8th Hospital,Department of Surgery
[6] Hubei Cancer Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 82卷
关键词：
Polymorphism; Irinotecan; Outcome; Metastatic colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：87 / 98
页数：11
相关论文
共 50 条
  • [1] UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy
    Yu, Qianqian
    Zhang, Tao
    Xie, Conghua
    Qiu, Hong
    Liu, Bo
    Huang, Liu
    Peng, Ping
    Feng, Jueping
    Chen, Jigui
    Zang, Aihua
    Yuan, Xianglin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 87 - 98
  • [2] A multicenter exploratory study of irinotecan-based chemotherapy on UGT1A1 polymorphisms for patients with colorectal cancer.
    Chikakiyo, Motoya
    Sato, Hirohiko
    Kurita, Nobuhiro
    Iwata, Takashi
    Yoshikawa, Kozo
    Kashihara, Hideya
    Mikami, Chie
    Matsumoto, Noriko
    Eto, Shohei
    Shimada, Mitsuo
    Hotchi, Masanori
    Okitsu, Hiroshi
    Sonaka, Yasuhide
    Yoshida, Sadahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [3] The comprehensive analysis of UGT1A genetic polymorphisms in patients with metastatic gastrointestinal cancer treated with irinotecan chemotherapy
    Tsujinaka, T.
    Satoh, T.
    Ura, T.
    Sasaki, Y.
    Yamazaki, K.
    Munakata, M.
    Yamada, Y.
    Ishizuka, N.
    Hyodo, I.
    Sakata, Y.
    EJC SUPPLEMENTS, 2009, 7 (02): : 144 - 144
  • [4] Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis
    Dan Liu
    Jian Li
    Jing Gao
    Yanyan Li
    Rui Yang
    Lin Shen
    BMC Cancer, 17
  • [5] Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis
    Liu, Dan
    Li, Jian
    Gao, Jing
    Li, Yanyan
    Yang, Rui
    Shen, Lin
    BMC CANCER, 2017, 17
  • [6] Refining the UGT1A Haplotype Associated with Irinotecan-Induced Hematological Toxicity in Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Irinotecan-Based Regimens
    Levesque, Eric
    Belanger, Anne-Sophie
    Harvey, Mario
    Couture, Felix
    Jonker, Derek
    Innocenti, Federico
    Cecchin, Erica
    Toffoli, Giuseppe
    Guillemette, Chantal
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 345 (01): : 95 - 101
  • [7] Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab
    Koutras, A. K.
    Antonacopoulou, A. G.
    Eleftheraki, A. G.
    Dimitrakopoulos, F-I
    Koumarianou, A.
    Varthalitis, I.
    Fostira, F.
    Sgouros, J.
    Briasoulis, E.
    Bournakis, E.
    Bafaloukos, D.
    Bompolaki, I.
    Galani, E.
    Kalogeras, K. T.
    Pectasides, D.
    Fountzilas, G.
    Kalofonos, H. P.
    PHARMACOGENOMICS JOURNAL, 2012, 12 (06): : 468 - 475
  • [8] Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab
    A K Koutras
    A G Antonacopoulou
    A G Eleftheraki
    F-I Dimitrakopoulos
    A Koumarianou
    I Varthalitis
    F Fostira
    J Sgouros
    E Briasoulis
    E Bournakis
    D Bafaloukos
    I Bompolaki
    E Galani
    K T Kalogeras
    D Pectasides
    G Fountzilas
    H P Kalofonos
    The Pharmacogenomics Journal, 2012, 12 : 468 - 475
  • [9] IS GENOTYPING OF UGT1A1 REALLY USEFUL FOR GYNECOLOGIC CANCER PATIENTS TREATED WITH IRINOTECAN-BASED CHEMOTHERAPY?
    Takano, M.
    Yoshikawa, T.
    Morikazu, M.
    Tadashi, A.
    Hiroaki, S.
    Kento, K.
    Hiroki, I.
    Hideki, I.
    Masaya, N.
    Takahiro, S.
    Takahiro, N.
    Hiroko, M.
    Tomoko, G.
    Hidenori, S.
    Yoshihiro, K.
    Kenichi, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1002 - 1002
  • [10] IS GENOTYPING OF UGT1A1 REALLY NEEDED FOR GYNECOLOGIC CANCER PATIENTS TREATED WITH IRINOTECAN-BASED CHEMOTHERAPY?
    Takano, M.
    Goto, T.
    Miyamoto, M.
    Kato, M.
    Sasaki, N.
    Aoyama, T.
    Soyama, H.
    Shibutani, T.
    Matsuura, H.
    Hirata, J.
    Sasa, H.
    Furuya, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1294 - 1294
12345